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Abstract  
Background: The current biomarkers alpha fetoprotein and human chorionic gonadotropin have 
limited sensitivity and specificity for diagnosing malignant germ cell tumours (GCTs). MicroRNAs 
(miRNAs) from the miR-371~373 and miR-302/367 clusters are over-expressed in all malignant 
GCTs and some of these miRNAs show elevated serum levels at diagnosis. Here, we developed a 
robust technical pipeline to quantify these miRNAs in serum and cerebrospinal fluid (CSF). The 
pipeline was used in samples from a cohort of exclusively paediatric patients with gonadal and 
extragonadal malignant GCTs, compared with appropriate tumour and non-tumour control groups. 
Methods: We developed a method for miRNA quantification that enabled sample adequacy 
assessment and reliable data normalisation. We performed qRT-PCR profiling for miR-371~373 and 
miR-302/367 cluster miRNAs in a total of 45 serum and CSF samples, obtained from 25 paediatric 
patients.  
Results: The exogenous non-human spike-in cel-miR-39-3p and the endogenous housekeeper miR-
30b-5p were optimal for obtaining robust serum and CSF qRT-PCR quantification. A four serum 
miRNA panel (miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-3p): i) showed high 
sensitivity/specificity for diagnosing paediatric extracranial malignant GCT; ii) allowed early 
detection of relapse of a testicular mixed malignant GCT; iii) distinguished intracranial malignant 
GCT from intracranial non-GCT tumours at diagnosis, using CSF and serum samples. 
Conclusions: The pipeline we have developed is robust, scalable and transferable. It potentially 
promises to improve clinical management of paediatric (and adult) malignant GCTs. 
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Introduction 
 
Germ cell tumours (GCTs) are characterised by clinical and pathological heterogeneity. They occur 
from the neonatal period through to late adulthood and arise at gonadal or extragonadal sites, 
including the central nervous system. Malignant GCTs are classified into germinoma and non-
germinomatous tumours [yolk sac tumour (YST), embryonal carcinoma (EC) and choriocarcinoma 
(CHC)], while teratomas (which show extensive somatic differentiation) are generally considered 
benign (Palmer et al, 2010). The utility of the conventional body fluid protein biomarkers alpha-
fetoprotein (AFP) and human-chorionic-gonadotropin (HCG) for diagnosis and follow-up is 
restricted to specific malignant GCT subtypes, as levels are raised predominantly in tumours 
containing YST and CHC, respectively (Murray & Nicholson, 2011). Moreover, both AFP and HCG 
can be elevated in non-malignant conditions (Murray et al, 2015a). The initial management of 
primary gonadal GCTs is complete resection where possible, regardless of serum AFP/HCG levels, 
thus enabling a histopathological diagnosis. For extragonadal primary sites of disease (e.g. the 
retroperitoneum and mediastinum), typical radiological findings and raised AFP/HCG markers alone 
may be sufficient for diagnosis, and indeed for intracranial GCTs this is the recommended practice 
in Europe and North America (Nicholson et al, 2002). For ‘marker-negative’ extragonadal cases, 
however, biopsy is required to establish a formal histopathological diagnosis. Such procedures carry 
risks of morbidity, due to the difficulties in surgical access to these anatomical sites. Furthermore, 
disease-monitoring after malignant GCT diagnosis to detect early non-symptomatic relapse currently 
relies heavily on serial radiological imaging, with associated cumulative radiation exposure and 
second malignant neoplasm risk (Tarin et al, 2009). Consequently, body fluid biomarkers that offer 
greater sensitivity and specificity for diagnosing and/or monitoring malignant GCTs would be of 
major clinical benefit (Murray et al, 2015a).  
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The ideal biomarker for malignant GCTs would be: stable within body fluids; abundant compared 
with levels in individuals who were healthy, had benign GCTs or non-GCT pathology; and present 
regardless of patient age (paediatric or adult), anatomical site of disease (gonadal or extragonadal, 
including intracranial) or histological subtype (e.g. YST, germinoma, EC) (Murray & Coleman, 
2012). Recent years have seen the emergence of microRNAs (miRNAs) as a new generation of 
biomarkers in malignant GCTs (Murray & Coleman, 2012). MicroRNAs are short, non-protein 
coding RNAs that are highly stable and well-suited for disease diagnosis and monitoring (Mitchell et 
al, 2008). We previously demonstrated that the eight main miRNAs from the miR-371~373 and 
miR-302/367 clusters were over-expressed in all malignant GCT tissues (Palmer et al, 2010). Using 
a multiplexed qRT-PCR protocol, we identified that levels of miRNAs from these two miRNA 
clusters were elevated in the serum of a paediatric patient at the time of diagnosis of an extragonadal 
malignant GCT, with levels falling and remaining low during uneventful clinical follow-up (Murray 
et al, 2011b). In the same year, we confirmed these serum findings in extracranial malignant GCTs 
across a range of representative ages (paediatric and adult), anatomical sites (gonadal and 
extragonadal) and histological subtypes (YST, germinoma and EC), the majority of which were 
AFP/HCG marker-negative (Murray & Coleman, 2012; Murray et al, 2011a). 
 
While our serum miRNA findings in malignant GCTs have since been confirmed and extended, the 
published studies have exclusively (Belge et al, 2012; Dieckmann et al, 2012; Rijlaarsdam et al, 
2015; Spiekermann et al, 2015a; Syring et al, 2015) or predominantly (Gillis et al, 2013) involved 
adult testicular tumours. In such cases, a consensus panel of four serum miRNAs from the miR-
371~373 and miR-302/367 clusters (namely miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-
3p) has been shown to be highly sensitive and specific for detecting GCTs (Gillis et al, 2013; Syring 
et al, 2015). The present study represents the first systematic interrogation of expression of these 
miRNA clusters in serum/CSF samples from patients with paediatric malignant GCTs. Our analysis 
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included serum levels at diagnosis for both ovarian and testicular disease, early detection of relapse 
and levels in cerebrospinal fluid (CSF) and serum in intracranial disease. Our investigation of the 
utility of these miRNAs is underpinned by the development of a robust pipeline for their 
quantification, including essential quality control steps. The pipeline is scalable, transferable and 
suitable for widespread adoption into routine clinical practice.  
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Materials and Methods 
The study received approval from the Multicentre Research Ethics Committee (reference 02/4/71) 
and Cambridge Local Research Ethics Committee (reference 01/128) and was performed with full 
informed parental consent. All experimental steps were compliant with the Minimum Information 
for Publication of Quantitative Real-time PCR Experiments (MIQE) (Bustin et al, 2009). Full details 
are available on request. 
 
Patient demographics and tumours analysed 
In total, we analysed 45 body fluid samples (serum n=41, CSF n=4), from a cohort of 25 paediatric 
patients (0-16 years) (Table 1). The cohort comprised a malignant GCT group [n=8; extracranial 
(n=5) and intracranial (n=3)]; a combined group comprising benign GCTs and non-GCT tumours 
[n=12; extracranial (n=10) and intracranial (n=2)] and a group of control subjects without tumours 
(n=5). The five extracranial malignant GCTs represented gonadal (three testicular, one ovarian) and 
extragonadal (sacrococcygeal) disease. The three intracranial GCTs represented two suprasellar site 
(one germinoma, one non-germinoma) and one pineal site (germinoma). The benign GCTs (n=5) 
comprised three immature teratomas (IT) and two mature teratomas (MT), from both gonadal (n=4) 
and extragonadal (n=1) sites. The sites of the non-GCT tumours (n=6) were: testicular/paratesticular 
(n=2; one sex cord stromal tumour, one rhabdomyosarcoma), ovarian [n=2; one simple cyst, one 
small cell carcinoma of the ovary, hypercalcaemic type (Bailey et al, 2015)] and intracranial (n=2; 
one suprasellar WHO grade 1 ganglioglioma and one disseminated MYCN-amplified 
neuroblastoma). The five samples in the control group were from five age- and gender-matched 
anonymised subjects, as described previously (Murray et al, 2015b). There were no statistical 
differences in age between the three patient groups. Full clinico-pathological details are given in 
Table 1. 
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Overview of pipeline development 
The pipeline developed for robust serum miRNA quantification is shown in Figure 1. Components 
of this pipeline are described in the following sections, with reference to the various colour-coded 
boxes in Figure 1.  
 
Sample processing and RNA extraction (Figure 1, Box A) 
As part of each patient’s standard clinical care, blood was sampled in serum separator tubes and 
CSF collected in plain tubes (Table 1). All specimens were sent to the routine clinical biochemistry 
diagnostic laboratories at Addenbrooke’s Hospital, Cambridge UK, where they were processed and 
centrifuged within four hours of receipt. After being used for routine clinical measurements, samples 
were kept refrigerated at 4oC for up to three days before residual serum/CSF was retrieved and then 
frozen and stored at -80oC. At each stage, all samples were processed according to good clinical and 
laboratory practice, including the use of disposable pipette tips. Only samples without macroscopic 
evidence of haemolysis were used (Murray et al, 2015b), to avoid substantial technical variation due 
to the release of intracellular miRNAs from red blood cells (Kirschner et al, 2011). 
 
RNA isolation 
RNA from 200μl of thawed serum or CSF samples was isolated using the miRNeasy serum kit 
(Qiagen, Crawley, UK), according to the manufacturer’s instructions. In order to increase RNA 
yield, we first added MS2 carrier RNA (Roche, Welwyn Garden City, UK) to QIAzol to give a final 
concentration of 1.25μg/ml (Murray et al, 2015b). To measure the RNA extraction efficiency, we 
also made a master mix of the exogenous non-human spike-in cel-miR-39-3p from the kit and added 
a fixed quantity (5.6x108 copies) to each sample (Murray et al, 2014), as per the manufacturer’s 
instructions. This fixed quantity resulted in subsequent cel-miR-39-3p qRT-PCR levels within the 
expected range for endogenous human serum miRNA levels (Murray et al, 2014). For samples 
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where 200μl was not available, volumes were made up to 200μl with an appropriate volume of 
1xPBS. Total RNA was eluted from columns with 100μl of nuclease-free water and stored at -80oC.  
 
Initial quality control (QC) assessment (Figure 1, Boxes B1-B3) 
Samples were screened for suitability for use in subsequent qRT-PCR analyses. Initial QC miRNA 
assessment was performed for: cel-miR-39-3p (non-human spike-in); miR-30b-5p (housekeeping 
miRNA); miR-23a-3p and miR-451a [used together for haemolysis assessment (Blondal et al, 
2013)]. For this initial QC step, miRNA reverse transcription (RT) and PCR reactions were 
performed in singleplex. Five μl of RNA was reverse transcribed using the TaqMan miRNA Reverse 
Transcription kit (Life Technologies, Paisley, UK) using the miRNA-specific stem-loop primer from 
the relevant TaqMan miRNA assay kit (Life Technologies) (Supplementary Table S1), as per the 
manufacturer’s instructions. The final volume of 15μl for each reaction underwent RT using a 
GeneAmp PCR System 9700 (Applied Biosystems) at 16oC for 30 minutes, 42oC for 30 minutes, 
followed by a final step of 85oC for 5 minutes, as described (Murray et al, 2011b). A singleplex final 
PCR was then performed as per the manufacturer’s instructions. This PCR was performed on a 
Mastercycler ep_gradient/S realplex (Eppendorf, Stevenage, UK) at 95oC for 10 minutes, followed 
by 45 cycles of 95oC for 15 seconds and 60oC for one minute, as described (Murray et al, 2014). To 
exclude non-specific amplification, a no-template control (NTC) was run for each assay in the QC 
step. In all cases, no product was detectable. 
 
Consistency of RNA extraction efficiency between samples was satisfactory, as measured by cel-
miR-39-3p levels [Cq range 19.4-23.7; standard deviation (SD) 1.28] (Figure 1, Box B2 and 
Supplementary Figure S1A). Serum levels of the housekeeping miRNA miR-30b-5p (Murray et al, 
2014) were also within the expected range (Cq range 23.7-28.8; SD 1.4) (Figure 1, Box B2 and 
Supplementary Figure S1B). Haemolysis assessment was performed using both miR-451a Cq 
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(Supplementary Figure S1C) and delta Cq (miR-23a-3p minus miR-451a) values (Figure 1, Box B3 
and Supplementary Figure S1D). This assessment showed that 37/41 samples (90.2%) had a delta 
Cq of <8 and therefore no substantial evidence of haemolysis (Blondal et al, 2013); three samples 
had a borderline delta Cq value of 8-9 and only a single sample demonstrated haemolysis (delta Cq 
10.2) (Supplementary Figure S1D). In the absence of further replicate non-haemolysed serum 
samples, we proceeded to full analysis of these four cases in our evaluation study, but with 
appropriate caution regarding the results. This approach allowed us to study the potential effects of 
sample haemolysis on candidate biomarker levels. 
 
MicroRNA (miRNA) quantification (Figure 1, Box C) 
Following initial QC assessment, the next phase of the pipeline was to quantify expression of a 
larger panel of target and housekeeping miRNAs (Supplementary Table S1). We first performed a 
multiplexed RT step. The TaqMan miRNA-specific stem-loop RT primers included those for the 
eight main miRNAs from the miR-371~373 and miR-302/367 clusters (Murray et al, 2011b), plus 
three miRNA housekeeping genes previously shown to be most stable in paediatric serum [namely 
miR-30b-5p, miR-30c-5p and miR-191-5p (Murray et al, 2014; Murray et al, 2015b)] and the non-
human spike-in technical control cel-miR-39-3p. To ensure sufficient product for the final PCR 
reactions, we performed two identical multiplexed RT reactions for each sample, using 5μl of RNA 
eluate in each, and an equal mixture of the relevant RT primers, adapted from (Murray et al, 2011b) 
(Supplementary Table S1). The final volume of 15μl for each reaction underwent RT, as described 
above for the initial QC phase. 
 
Multiplexed pre-amplification of RT product (Figure 1, Box C) 
For the pre-amplification step, reactions were multiplexed using the relevant TaqMan assay probes, 
as described (Murray et al, 2011b). As pre-amplification of specific RT products increases target 
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abundance without introducing bias (Murray et al, 2011b), this allowed greater assay sensitivity and 
increased the number of target miRNAs measured from the small starting volume. Briefly, an equal 
mix of all 20x TaqMan assay probes was prepared for each reaction and diluted to 0.2x with 1x Tris-
EDTA buffer (pH 8.0), as described (Murray et al, 2011b). Two identical pre-amplification 
reactions (each 50μl) for each sample contained 25μl of 2x pre-amplification master mix (Life 
Technologies), 25μl of the diluted TaqMan assay probe mix and 12.5μl of multiplexed cDNA 
product (Murray et al, 2011b). After heating to 95oC for 10 minutes, 14 cycles of 95oC for 15 
seconds and 60oC for 4 minutes were run on the GeneAmp PCR System 9700 (Murray et al, 2011b). 
The resulting reaction products were diluted 1:5 with nuclease-free water, and then the two pre-
amplification reaction products for each individual sample were pooled, to make a final volume of 
500μl, sufficient to perform all subsequent singleplex final miRNA PCR reactions in triplicate.  
 
Final singleplexed PCR of pre-amplification product (Figure 1, Box C) 
Nine μl of the diluted pre-amplified cDNA product was added to 10μl of TaqMan 2x Universal PCR 
Master Mix, No AmpErase UNG (Applied Biosystems) and 1μl of each individual 20x TaqMan 
assay probe, thereby maintaining ratios identical to those previously described (Murray et al, 
2011b). All reactions were performed in triplicate. PCR was performed using the conditions 
described above for the initial QC phase. For both the QC (Figure 1, Boxes B1-B3) and the miRNA 
quantification steps (Figure 1, Box C), the Cq threshold was set manually to 2,000 fluorescence 
units across all PCR plates. NTC samples were also run in the miRNA quantification step; raw mean 
NTC Cq values are listed in Supplementary Table S1. Test miRNAs with results within two Cq 
values of the NTC sample or greater were classed as non-expressing. 
 
Data normalisation and analysis (Figure 1, Box D) 
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In the miRNA quantification step (Figure 1, Box C), cel-miR-39-3p and miR-30b-5p were again 
measured, to allow assessment of the technical reproducibility of the pipeline. A highly significant 
correlation was observed between the Cq values obtained in the initial QC (Figure 1, Box B) and the 
miRNA quantification steps (Figure 1, Box C), for both cel-miR-39-3p and miR-30b-5p (R2=0.937, 
p<0.0001 and R2=0.867, p<0.0001; respectively) (Supplementary Figure S1E). 
 
When analysing the miRNA quantification data (Figure 1, Box C), we first normalised expression of 
the three endogenous housekeeping miRNAs miR-30b-5p, miR-30c-5p and miR-191-5p (Murray et 
al, 2014; Murray et al, 2015b) to cel-miR-39-3p, in order to account for any differences in 
efficiency of the RNA extraction and RT steps. All three housekeeping miRNAs were found to be 
stably expressed across all 41 serum samples (Figure 2A). Importantly, all the miRNAs used for 
housekeeping purposes are transcribed from independent chromosomal loci [miR-30b-5p 
(chromosomal locus 8q24); miR-30c-5p (6q13); miR-191-5p (3p21.31) and miR-23a-3p (19p13.3)] 
(Murray et al, 2015b). Furthermore, all have previously been shown to be abundant and stably 
expressed in serum from both paediatric and adult (Blondal et al, 2013) patients. For the four serum 
samples that showed evidence of haemolysis (grey arrows in Figure 2A), expression levels of these 
three microRNAs still fell within the normal range, demonstrating their suitability for housekeeping 
purposes. 
 
By linear regression analysis, levels of cel-miR-39-3p correlated with each of the three endogenous 
housekeeping miRNAs, miR-30b-5p, miR-30c-5p and miR-191-5p (Figure 2B), although R2 values 
were only modest, at 0.679, 0.418 and 0.421, respectively. To confirm that cel-miR-39-3p provided 
additional stringency when using the housekeeping miRNAs for data normalisation, we compared 
levels of all three with each other, both before (Figure 2C) and after (Figure 2D) cel-miR-39-3p 
correction. While the three housekeeping miRNAs showed positive correlations with each other in 
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all comparisons (p<0.0001), addition of cel-miR-39-3p normalisation increased the R2 values in all 
cases (miR-30b-5p vs. miR-30c-5p, R2 0.857 to 0.925; miR-30b-5p vs. miR-191-5p, R2 0.824 to 
0.877; miR-30c-5p versus miR-191-5p, R2=0.888 to 0.904) (Figure 2C/2D).  
 
The standard deviation of the serum Cq values across the whole cohort of 41 samples was lowest for 
miR-30b-5p (1.16), when compared with miR-30c-5p (1.52) and miR-191-5p (1.51). Consequently, 
miR-30b-5p was selected for normalisation of target miRNA quantification data, following 
normalisation of the miR-30b-5p Cq values to the cel-miR-39-3p levels determined in the miRNA 
quantification step (Figure 1, Box D). Target miRNA levels were quantified relative to miR-30b-5p 
using the delta Cq method, as described (Murray et al, 2014; Murray et al, 2015b). For further 
details, see Supplementary Materials and Methods. In this evaluation study we applied very 
stringent criteria for defining miRNA over-expression, whereby only serum miRNA levels that 
showed a ≥2.0 fold change in expression (Murray et al, 2014; Murray et al, 2015b) compared with 
the highest level from the non-tumour control group were considered positive. Differences in serum 
miRNA levels between experimental groups were assessed using the Mann-Whitney U test (p<0.05 
significant). 
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Results  
A four serum miRNA panel (miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-3p) enables 
sensitive diagnosis of paediatric extracranial malignant GCTs 
In group comparisons, normalised levels of four miRNAs were significantly higher in the serum of 
paediatric patients with extracranial malignant GCT, compared with both the combined benign 
GCT/non-GCT tumour group and the non-tumour control group (Figure 3A). This panel comprised 
the three main miRNAs from the miR-371~373 cluster (miR-371a-3p, miR-372-3p and miR-373-
3p), plus miR-367-3p from the miR-302/367 cluster. Normalised serum levels of miR-302a-c were 
not consistently detected above the control threshold in malignant GCT patients (data not shown). 
As miR-302d-3p levels in all test samples were within two Cq values of the NTC sample, this 
miRNA was excluded from subsequent analyses. 
 
When assessing cases individually, using our highly stringent criteria for defining miRNA over-
expression, positive results were seen in four out of five extracranial malignant GCTs for miR-371a-
3p; five of five for miR-372-3p; two of five for miR-373-3p and three of five for miR-367-3p 
(Figure 3B and Supplementary Figure S2A-D). There was no obvious association between test 
miRNA levels and the presence of haemolysis in this small sample set. The greatest dynamic range 
in levels was seen for miR-371a-3p, which also showed the clearest separation between positive and 
negative samples - for example, the lowest level of miR-371a-3p observed in a positive sample 
(MGCT_ExC#3) was 10-fold higher than the highest non-tumour control (CONT_5) 
(Supplementary Figure S2A). Interestingly, we did not detect miR-371a-3p over-expression in a 
serum sample reportedly taken at the time of diagnosis of an ovarian YST (MGCT_ExC#4) 
(Supplementary Figure S2A). Further enquiry revealed that the sample had in fact been taken four 
days following complete resection of the ovarian primary tumour, rather than prior to surgery. This 
is consistent with the described very short half-life for miR-371a-3p in the serum, where the major 
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source has been removed (Dieckmann et al, 2015; Spiekermann et al, 2015a). On the other hand, 
other members of the four miRNA panel identified remained elevated in this serum sample 
(Supplementary Figure S2). Together, these observations demonstrated the value of using the whole 
panel in detecting extracranial malignant GCTs, including where the timing of the ‘diagnostic’ 
serum sample was suboptimal. In our dataset, miR-372-3p was the only serum miRNA that was 
elevated in all cases of extracranial malignant GCT. 
 
Receiver operator characteristic (ROC) analysis, based on varying cut-offs for defining miRNA 
over-expression, showed that each of the four members of the miRNA panel, miR-371a-3p, miR-
372-3p, miR-373-3p and miR-367-3p, were independently highly sensitive and specific for 
differentiating paediatric extracranial malignant GCT cases (n=5) from a combined group (n=15) 
consisting of both the extracranial benign GCT/non-GCT tumour cases and the non-tumour control 
samples (Figure 3C). We also compared raw Cq (non-normalised) and delta Cq (normalised) values 
for the four serum miRNA panel (Supplementary Figure S2E), following recent reports suggesting 
that relative quantification using normalisation to a housekeeping miRNA may not be required when 
quantifying serum miRNAs for detection of malignant GCTs (Spiekermann et al, 2015b). We 
observed a close correlation between raw Cq and delta Cq values for miR-371a-3p (R2=0.969), but 
for miR-372-3p, miR-373-3p and miR-367-3p the correlation values were lower (R2= 0.792, 0.824 
and 0.773, respectively) (Supplementary Figure S2E). 
 
Serum miRNA levels allow early detection of relapse during longitudinal follow-up for 
extracranial (testicular) malignant GCT. 
We assessed the value of the miR-371~373 and miR-302/367 cluster miRNAs for early detection of 
relapse in malignant GCT. We examined 18 samples obtained during diagnosis, treatment and 
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follow-up [to day (d) 782] from a patient with a stage 1 testicular mixed malignant GCT (Figure 4). 
For full clinical details of the case, see Supplementary Results (clinical case 1). 
 
The primary tumour contained YST, EC, CHC and IT components. At the time of diagnosis, the 
serum levels of miR-371a-3p, miR-372-3p and miR-367-3p were elevated [10.1, 2.6 and 2.1-fold 
respectively, compared with the highest non-tumour control (Supplementary Figure S2A-D)]. Seven 
of the eight main miRNAs (miR-302d-3p excluded) from the miR-371~373 and miR-302/367 
clusters were profiled in 17 further longitudinal serum samples. After resection of the primary 
tumour, levels of miR-371a-3p and miR-372-3p decreased to baseline by d14 (Figure 4C/4D, 
respectively). At the time of radiologically detected relapse of malignant disease on d28 (Figure 4E), 
AFP did not increase, while HCG levels showed only a modest increase of 35.4% from their 
previous values at d14 (Figure 4A/4B, respectively). In striking contrast, miR-371a-3p increased 
from a relative level of 25.2 on d14, to 100.3 at d28 (398% increase) and 220.7 at d33 (876% 
increase) (Figure 4C). Levels of miR-372-3p also increased at this time, albeit more modestly 
(Figure 4D). 
 
Once treatment of the malignant relapse commenced (d33), levels of miR-371a-3p and miR-372-3p 
decreased rapidly to baseline (Figure 4C/4D), whereas both AFP and HCG showed an initial ‘flare’ 
(observed at d42) (Figure 4A/4B), before falling to baseline. Further lymph node enlargement 
detected radiologically at the end-of-treatment at d101 was not associated with elevations of these 
miRNAs (nor of AFP/HCG) (Figure 4). Following retroperitoneal lymph node dissection (at d140), 
histopathology showed a diagnosis of growing teratoma syndrome [a non-malignant condition; 
(Logothetis et al, 1982)], rather than further malignant relapse. In uneventful subsequent clinical 
follow-up from d140 to d782, AFP/HCG, miR-371a-3p and miR-372-3p levels all remained 
negative (Supplementary Figure S3A). By linear regression analysis of all 18 longitudinal samples, 
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levels of AFP, HCG, miR-371a-3p and miR-372-3p each correlated significantly with the other 
three markers (Supplementary Figure S3B), with the strongest correlation being between miR-371a-
3p and miR-372-3p levels (R2=0.909; p<0.0001). Outlier points in the serum miRNA and AFP/HCG 
correlations reflected the more pronounced changes in serum miRNA levels at the time of  
malignant relapse (at d28; red arrows in Supplementary Figure S3B) and the lack of a serum miRNA 
flare immediately following administration of chemotherapy (d42; green arrows in Supplementary 
Figure S3B). 
 
Serum and CSF miRNA levels distinguish intracranial malignant GCTs from intracranial 
non-GCT pathology in paediatric patients. 
To determine if the four miRNA panel comprising miR-371a-3p, miR-372-3p, miR-373-3p and 
miR-367-3p could be used to detect intracranial malignant GCT disease, we measured the levels of 
these miRNAs in four serum and four CSF samples, obtained from a total of five patients (Table 1 
and Figure 5). For full clinical details of these cases, see Supplementary Results (clinical cases 2). 
 
Serum levels of miR-371a-3p and miR-373-3p were positive in the intracranial malignant GCT 
patients MGCT_IC#3 and MGCT_IC#1, respectively (Figure 5B), both of whom had negative 
serum and CSF AFP/HCG levels. None of the other miRNAs tested was positive in the other serum 
samples, using the previously specified serum cut-offs. We extracted RNA from CSF of four 
patients (MGCT_IC#2, MGCT_IC#3, B-non-GCT_IC#1 and M-non-GCT_IC#1). The M-non-
GCT_IC#1 case was a 2-year-old male with MYCN-amplified neuroblastoma (Murray et al, 2015b), 
who developed intracranial metastatic disease during treatment (Table 1). In each case, a fixed 
quantity of non-human spike-in cel-miR-39-3p was added, as for the serum samples. We quantified 
the levels of cel-miR-39-3p, the three housekeeping miRNAs that we had shown to be stable in the 
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serum (miR-30b-5p, miR-30c-5p and miR-191-5p), and miR-124-3p, which had previously been 
suggested as a suitable CSF housekeeping miRNA (Exiqon, 2013). 
 
Levels of cel-miR-39-3p recovery from the four CSF samples obtained in the miRNA quantification 
step were equivalent to those observed with the serum sample cohort (mean Cq cel-miR-39-3p CSF 
13.27 ± SD 0.12 vs. serum 13.98 ± SD 0.26) (Supplementary Figure S4A). However, miR-124-3p 
levels showed a >6 Cq difference across the CSF samples. The greatest miR-124-3p abundance in 
the CSF was in the MYCN-amplified neuroblastoma sample (M-non-GCT_IC#1) (Supplementary 
Figure S4A), consistent with our previous findings that miR-124-3p is a disease-associated serum 
biomarker (Murray et al, 2015b). Together, these data indicate that miR-124-3p is not a good 
candidate for CSF normalisation. In contrast, all three of the other housekeeping miRNAs tested 
were very stable across the small number of CSF samples examined, albeit with higher mean Cq 
values than in the serum samples (miR-30b-5p, 17.0 vs. 14.9; miR-30c-5p, 19.0 vs. 15.7 and miR-
191-5p, 16.5 vs. 13.6, respectively) (Supplementary Figure S4A). Similar to our observations in the 
serum samples, we identified that the optimal CSF housekeeping miRNA was miR-30b-5p, which 
had a lower standard deviation (0.18) than miR-30c-5p (0.53), miR-191-5p (0.21) and miR-124-3p 
(3.0) (Supplementary Figure S4A). 
 
As with the serum samples, we also quantified CSF levels of miR-23a-3p and miR-451a to assess 
haemolysis (Supplementary Figure S4B). Despite all four CSF samples being clear and colourless 
on visual inspection (i.e. showing no evidence of haemolysis), two were above the serum 
haemolysis threshold (delta Cq >8) using standard methodology (Blondal et al, 2013) 
(Supplementary Figure S4B). Individual miR-451a Cq values for all four CSF samples were higher 
than the mean miR-451a level for haemolysis-negative serum samples (delta Cq <8, n=37) 
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(Supplementary Figure S4B), while mean miR-23a-3p Cq values were also higher in CSF samples 
(31.9) compared with serum (23.3).  
 
The levels of miR-371~373 and miR-302/367 were then measured in the three available diagnostic 
CSF samples from patients with primary intracranial tumours (MGCT_IC#2, MGCT_IC#3 and B-
non-GCT_IC#1) (Figure 5C). The normalisation and stringent cut-off procedures used for serum 
samples were applied, with miRNAs that had a ≥2.0 fold-change in expression compared with the 
highest serum level from the non-tumour control group being considered positive. Using these 
criteria, CSF miR-371a-3p and miR-372-3p levels clearly distinguished the intracranial malignant 
GCTs from the non-malignant (ganglioglioma) case (Figure 5C). In addition, CSF levels of miR-
373-3p, miR-367-3p, miR-302a-3p and miR-302b-3p were also positive in the MGCT_IC#3 
germinoma case (Figure 5C). The raw (non-normalised) Cq values for the four miRNAs in the panel 
identified from serum analysis were similar in the positive and negative CSF samples to those in the 
positive and negative serum samples, respectively (Supplementary Figure S4C), suggesting there 
was approximate equivalence in the overall abundance of these miRNAs in serum and CSF. 
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Discussion 
 
We report a robust, quality controlled pipeline for measuring levels of specific serum and CSF 
miRNAs in paediatric patients with extracranial and intracranial malignant GCTs. The pipeline 
benefits from an exogenous non-human spike-in control (cel-miR-39-3p), normalisation using an 
endogenous housekeeping miRNA (miR-30b-5p) and haemolysis quantification (Blondal et al, 
2013).Variation in exogenous cel-miR-39-3p levels between samples may be reported as differences 
in Cq values (Yamada et al, 2014) or recovery rates (Sanders et al, 2012). The variation we 
observed in cel-miR-39-3p levels in our cohort, of ~4 Cq cycles, reflects the genuine difference in 
RNA recovery between serum samples, which must be normalised to avoid creating false 
negative/positive results. This variation is consistent with other reports [e.g. (Yamada et al, 2014)] 
and less than that described in other studies, which e.g. report a recovery rate of 1-56% (i.e. 
variation of ~6 Cq values) (Sanders et al, 2012). 
 
The correlation data in our relatively small study also indicate an additional benefit of normalising 
to a stable, endogenously expressed miRNA, i.e. miR-30b-5p. This second normalisation step 
accounts for differences between overall circulating endogenous miRNA levels in individuals, 
which is not addressed using cel-miR-39-3p levels alone. Our data indicate that this highly stringent 
pipeline, including two normalisation steps, minimises technical alterations and maximises detection 
of true biological variation between serum samples. It will be important for prospective studies to 
evaluate the relative contributions of the two normalisation steps to the avoidance of potential false 
negative/positive results. In future, once assessed fully, it may be possible to relax the proposed 
normalisation stringency in circulating microRNA studies. 
 
For CSF analysis, we have shown that miR-30b-5p is stable in a small cohort of samples, 
demonstrating minimal variation, and may therefore also be suitable for normalisation in future CSF 
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studies. In contrast to previous suggestions (Exiqon, 2013), miR-124-3p does not appear appropriate 
as a housekeeping gene for CSF normalisation and indeed has been identified as a candidate tumour 
biomarker in its own right (Murray et al, 2015b). 
 
Haemolysis assessment may also be important during initial QC, as variations in red blood cell lysis 
between samples may result in altered serum expression levels of miRNAs of interest for technical, 
rather than biological, reasons (Pritchard et al, 2012). There are a number of methods for such 
assessment, including the measurement of free haemoglobin (Kirschner et al, 2011), or the 
established use of delta Cq (miR-23a-3p minus miR-451a) levels (Blondal et al, 2013; Exiqon, 
2013; Ludwig et al, 2015; Murray et al, 2015b). The haemolysis results described here, using the 
latter approach, appear comparable in terms of cut-off thresholds to data obtained utilising different 
qRT-PCR platforms (Blondal et al, 2013; Ludwig et al, 2015). Haemolysis did not appear to have 
any major effect on the levels of our candidate biomarkers from the miR-371~373 and miR-302/367 
clusters, albeit based on a low sample size. However, as it will be critical to avoid false positive 
results when such tests are established in clinical practice, we recommend that haemolysis 
assessment should be performed prospectively in circulating miRNA studies, to define precisely 
what effect haemolysis has on candidate biomarkers in borderline cases. Of note, the miRNA 
quantification method used to indicate haemolysis in serum samples was not appropriate for CSF, 
where alternative approaches are required. 
 
From our profiling of all eight main members of the miR-371~373 and miR-302/367 clusters, we 
derived a panel of four miRNAs that is capable of accurately detecting both extracranial and 
intracranial malignant GCT disease in paediatric patients (see Supplementary Discussion). 
Interestingly, the same panel was shown to be of diagnostic value in adults with testicular malignant 
GCTs (Gillis et al, 2013; Syring et al, 2015). In contrast to recent reports (Dieckmann et al, 2015; 
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Spiekermann et al, 2015a; Spiekermann et al, 2015b), miR-371a-3p alone was not sufficient to 
identify some malignant GCTs in our patient cohort, including in serum from a patient with an 
intracranial (pineal) germinoma, where only miR-373-3p was positive. Moreover, the particularly 
rapid reduction in miR-371a-3p levels following tumour removal in stage 1 disease (Dieckmann et 
al, 2015; Spiekermann et al, 2015a) will lead to negative results in samples taken more than one day 
post-surgery, unlike the other miRNAs in the panel. Our data suggest that expression in body fluids 
of the four miRNAs in the panel varies across the spectrum of malignant GCT patients and that the 
full panel provides maximal sensitivity, without affecting specificity. Accordingly, elevated levels of 
one (or more) member(s) of the panel would represent a positive test result. As miR-367-3p is 
transcribed from a separate chromosome locus (4q25) to the other three miRNAs from the miR-
371~373 cluster (19q13.41), elevated serum miR-367-3p levels would add confidence to a diagnosis 
of malignant GCT, as distinct from other malignancies that over-express miR-371~373 miRNAs but 
not miR-367-3p. Such tumours include carcinomas of the stomach (Liu et al, 2012) and pancreas 
(He et al, 2014), as well as primary intracranial tumours with genomic amplification of 19q13 
(Korshunov et al, 2010; Pfister et al, 2009).  
 
We have shown, for the first time, that miRNAs from the four serum miRNA panel can sensitively 
detect malignant GCT relapse during longitudinal follow-up. In the case studied, miR-371a-3p and 
miR-372-3p detected relapse of an AFP/HCG-secreting (‘marker-positive’) testicular mixed 
malignant GCT. Indeed, our data suggest that the miRNAs are more sensitive at detecting malignant 
relapse than conventional protein biomarkers, as they provided a clear positive result at the initial 
time of radiological relapse (d28), when HCG levels showed only a modest increase and AFP levels 
had not changed. In addition, miR-371a-3p and miR-372-3p appeared to give a more accurate 
measure of early response to therapy, as, unlike AFP and HCG, levels did not flare following 
initiation of chemotherapy. Longitudinal monitoring of further extracranial malignant GCT cases 
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using this panel of serum miRNAs is likely to demonstrate their clinical utility in the follow-up of 
‘marker-negative’ cases. In due course, serum miRNA monitoring in malignant GCT patients may 
reduce the need for serial CT scans, the associated radiation exposure and second cancer risk (Tarin 
et al, 2009). 
 
It has recently been suggested that it may not be necessary to perform relative quantification when 
assessing serum miRNAs as a potential test for testicular malignant GCTs and that raw Cq values 
provide adequate diagnostic discrimination (Spiekermann et al, 2015b). Our data suggest that 
overall this is a suboptimal approach when using current methodology. Serum miR-371a-3p has a 
large dynamic range, allowing a greater degree of separation between positive and negative samples 
in our study. For this miRNA, the raw Ct (non-normalised) and delta Ct (normalised) values 
demonstrated a very strong correlation (R2=0.969). However, for the other three miRNAs in the four 
serum panel (namely miR-372-3p, miR-373-3p and miR-367-3p), the dynamic range was lower. The 
difference in mean Cq value between positive and negative samples was ~4 and the R2 correlation 
for Cq and delta Cq values were also lower at 0.792, 0.824 and 0.773, respectively. For such 
miRNAs, differences in extraction efficiency will have a relatively high impact on PCR 
measurements and will require careful control via relative quantification approaches. Methods that 
also use data normalisation will also enable analysis of low volume samples (<200μl), for which 
dilution is required to produce a suitable starting volume. Such a scenario is particularly likely to 
occur in specimens from paediatric patients and/or certain sample types, such as CSF. 
 
In due course, robust absolute quantification systems may supersede relative quantification when 
measuring miRNA levels in body fluids (Hindson et al, 2013), although the use of a non-human 
spike-in or other appropriate ‘standard’ will still need to be employed, to ensure the accuracy of 
RNA extraction steps and subsequent quantification within and between samples (Sanders et al, 
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2012). Determining absolute miRNA counts per set volume of serum would allow the determination 
of universal cut-offs e.g. for miR-451a in assessing haemolysis and for the four miRNA panel in 
diagnosing malignant GCT. This should improve sensitivity and specificity overall and provide 
greater confidence in ‘borderline’ cases, ensuring that diagnostic decisions are not undermined by 
subtle technical differences. This is important for translation into the clinic, where minimisation of 
potential false negative/positive results is critical. 
 
In conclusion, we have described a robust pipeline for diagnosis and monitoring of extracranial and 
intracranial paediatric malignant GCTs. The technical principles and clinical observations described 
here will underpin the future clinical validation work that is now warranted.  
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Table and Figure Legends 
 
 
Table 1. Clinico-pathological details of samples and patients analysed.  
 
Figure 1. Pipeline for quantifying miRNA levels in serum using qRT-PCR.  
 
Figure 2. Levels of housekeeping miRNAs in the quantification phase of the pipeline (Figure 1, 
Box C). A) Cq values for the housekeeping miRNAs miR-30b-5p, miR-30c-5p and miR-191-5p, 
obtained after normalisation to cel-miR-39-3p, in all 41 serum samples tested in this study. Sample 
numbers correspond to those in Table 1. The four samples that had a delta Cq (miR-23a-3p minus 
miR-451a) value >8 in the QC step (Figure 1, Box B3) are indicated by arrows. B) Correlations 
between the raw Cq values for the housekeeping miRNAs in A) above and the raw cel-miR-39-3p 
Cq values. C) and D) Correlations between the raw (C) and cel-miR-39-3p-normalised (D) Cq 
values of the three housekeeping miRNAs in all serum samples tested: miR-30b-5p vs. miR-191-5p 
(left panel), miR-30c-5p vs. miR-191-5p (centre) and miR-30b-5p vs. miR-30c-5p (right). 
 
Figure 3. Relative levels of serum miRNAs in the quantification phase of the pipeline (Figure 
1, Box C) based on samples from patients with extracranial disease. A) Levels in the three 
patient groups of: i) miR-371a-3p, ii) miR-372-3p, iii) miR-373-3p and iv) miR-367-3p by box-and-
whisker plot. The broken horizontal line in each graph represents the cut-offs derived from the 
serum samples, i.e. 2.0 times the highest level seen in the non-tumour control group. Box = 
interquartile range; whiskers = full range of data. B) Summary heatmap of levels of each member of 
the four miRNA panel in serum samples from patients at the time of diagnosis of extracranial 
disease. Positive results (i.e. miRNA levels ≥2.0 fold above the highest level observed in the non-
tumour control group) are displayed as black boxes. For abbreviations, see Table 1. C) Individual 
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receiver operator characteristic (ROC) curves for each member of the four miRNA panel, namely: i) 
miR-371a-3p, ii) miR-372-3p, iii) miR-373-3p and iv) miR-367-3p. AUC = area under the curve. 
 
Figure 4. Follow-up of a patient with a testicular mixed malignant GCT (MGCT_ExC#3). 
Panels A and B show levels of the serum protein biomarkers AFP and HCG, respectively, while 
panels C and D show levels of miR-371a-3p and miR-372-3p, respectively, from d0 (diagnosis) to 
d160 of follow-up. Asterisks denote the clinical stages of: diagnosis (1), malignant relapse (2), end-
of-treatment (3) and retroperitoneal lymph node dissection (RPNLD) (4). The arrows show the 
timing of each chemotherapy cycle. Panel E shows representative CT scan images at the four time-
points described above. The arrows show the retroperitoneal disease. 
    
Figure 5. Relative levels of serum and CSF miRNAs for diagnosis of primary intracranial 
GCTs. A) MRI images for three patients with primary intracranial tumours, namely: i) a suprasellar 
non-germinomatous GCT (MGCT_IC#2), ii) a suprasellar germinoma (MGCT_IC#3) and iii) a 
ganglioglioma (B-non-GCT_IC#1). B) Serum levels of: i) miR-371a-3p and ii) miR-373-3p, 
measured in the three patients with primary intracranial disease shown in A), plus a fourth with a 
primary intracranial pineal germinoma (MGCT_IC#1). C) CSF levels of: i) miR-371a-3p, ii) miR-
372-3p, iii) miR-373-3p, iv) miR-367-3p, v) miR-302a-3p and vi) miR-302b-3p in the three patients 
with primary intracranial disease shown in A). Thresholds (dotted lines) are as in Figure 3. Error 
bars = SEM. 
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